Toxicity and dosimetry of 177Lu-DOTA-Y3-octreotate in a rat model
✍ Scribed by Jason S. Lewis; Mu Wang; Richard Laforest; Fan Wang; Jack L. Erion; Joseph E. Bugaj; Ananth Srinivasan; Carolyn J. Anderson
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- French
- Weight
- 84 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0020-7136
- DOI
- 10.1002/ijc.1540
No coin nor oath required. For personal study only.
✦ Synopsis
Radiolabeled somatostatin analogs have demonstrated effectiveness for targeted radiotherapy of somatostatin receptor-positive tumors in both tumor-bearing rodent models and humans. A radionuclide of interest for cancer therapy is reactor-produced 177 Lu (t 1/2 ؍ 6.64 d;  ؊ [100%]). The high therapeutic efficacy of the somatostatin analog 177 Lu-DOTA-Tyr 3 -octreotate (DOTA-Y3-TATE, where DOTA is 1,4,7,10tetraazacyclododecane-1,4,7,10-tetraacetic acid) was previously demonstrated in a tumor-bearing rat model (Erion et al.,
📜 SIMILAR VOLUMES
## Abstract Peptide receptor scintigraphy with [^111^In‐DTPA^0^]octreotide (a stabilized radiolabeled somatostatin (SS) analogue, OctreoScan®) is widely used for the visualization and staging of somatostatin receptor‐positive tumors. The application of likewise somatostatin analogues as vehicle for
## Abstract Loss of integrity of the blood–brain barrier (BBB) and brain swelling is a potentially lethal complication of reperfusion in human stroke. To assess the time course of BBB modifications, we performed angiography, diffusion‐weighted imaging, __T__1‐weighted (__T__~1~W) imaging and __T__~